Overall rank by patents
#26,276
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A01M (CATCHING, TRAPPING OR SCARING OF ANIMALS ; APPARATUS FOR THE DESTRUCTION OF NOXIOUS ANIMALS OR NOXIOUS PLANTS).
The verdict
Expedite holds 10 US patents across 6 technology areas, rank #26,276 of 50,000 tracked assignees.
Expedite International has been granted 10 US utility patents between 2019 and 2025, placing Expedite International at rank #26,276 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 5.5 claims per patent with primary concentration in A01M (CATCHING, TRAPPING OR SCARING OF ANIMALS ; APPARATUS FOR THE DESTRUCTION OF NOXIOUS ANIMALS OR NOXIOUS PLANTS). As a US Corporation, Expedite International is one of the more focused assignees in the PatentsView dataset. By volume, Expedite sits between Exacta Systems, Llc (10 patents, rank #26,272) and Farmhannong Co., Ltd (10 patents, rank #26,280) - the closest US assignees by grant volume. The composite Innovation Score of 25.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 9 grants, compared with 1 in the 2015–2019 window, a +800% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Expedite International's 5.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Expedite International against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Exacta Systems, LLC
10 patents
Excalibur Pharmaceuticals, Inc.
10 patents
Excelfore Corporation
10 patents
Exnodes Inc.
10 patents
EyeCue Vision Technologies Ltd.
10 patents
FAIRCHILD (TAIWAN) CORPORATION
10 patents
FAMOSA CORP.
10 patents
FARMHANNONG CO., LTD
10 patents
Expedite International
10 patents
What this shows Expedite holds 10 patents at rank #26,276, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Expedite's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
26 Top 82% higher than 18% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 10.0% |
| 2020 | 2 | 20.0% |
| 2021 | 2 | 20.0% |
| 2022 | 1 | 10.0% |
| 2023 | 2 | 20.0% |
| 2024 | 1 | 10.0% |
| 2025 | 1 | 10.0% |
Top 6 of 6 technology areas
Overall rank by patents
#26,276
Across all tracked assignees
25.6 out of 100
How to use this portfolio
Expedite's 10 grants land it in the top 82% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.